Atara Biotherapeutics Stock News

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Tactile Systems Technology ( TCMD – Research Report ) and Aileron Therapeutics ( ALRN – Research Re

Atara Biotherapeutics upgraded to Buy from Neutral at Citi Citi ATRA

Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune and viral diseases, today

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Biogen (BIIB) and Medtronic (MDT). Biogen (BIIB) Mizuho Securities

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Biogen ( BIIB – Research Report ) and Medtronic ( MDT – Research Report ). Biogen (BIIB) Mizuho Securities analyst

Bank of America Corp DE cut its stake in Atara Biotherapeutics Inc (NASDAQ:ATRA) by 28.5% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (

In the market for an education-focused Chromebook? These are our favorite ones!

Norges Bank bought a new position in shares of Atara Biotherapeutics Inc (NASDAQ:ATRA) during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC)

Geode Capital Management LLC lifted its holdings in shares of Atara Biotherapeutics Inc (NASDAQ:ATRA) by 5.3% during the 4th quarter, according to its most recent disclosure with the SEC. The fund own

Atara Biotherapeutics Inc (NASDAQ:ATRA)’s share price fell 2.5% during trading on Thursday . The company traded as low as $7.64 and last traded at $7.72, 29,474 shares changed hands during mid-day t

Wall Street analysts predict that Atara Biotherapeutics Inc (NASDAQ:ATRA) will announce earnings of ($1.36) per share for the current fiscal quarter, according to Zacks Investment Research. Zero analy

There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Pfenex (PFNX) and Autolus Therapeutics (AUTL) with bullish

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Pfenex (PFNX

Mizuho Securities analyst Salim Syed maintained a Buy rating on Gilead Sciences (GILD) today and set a price target of $81.00. The company's shares closed